latisse

Latisse Faces Patent Challenge

July 13, 2010 · Posted in Healh News · Comment 

The FDA said a company is challenging Allergan’s patent protection for the eyelash drug Latisse, looking to make a generic version. (Source: WSJ.com: Health)

See the rest here:
Latisse Faces Patent Challenge

FDA: Allergan’s Web Site Is Misleading

September 16, 2009 · Posted in Healh News · Comment 

The FDA said the Web site of Allergan’s Latisse is misleading because it suggests the company’s eyelash thickener is more safe than proven. (Source: WSJ.com: Health)

View post:
FDA: Allergan’s Web Site Is Misleading

Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse — First and Only Treatment Approved by the FDA for Hypotrichosis of…

December 29, 2008 · Posted in Healh News · Comment 

IRVINE, Calif.–(BUSINESS WIRE)–Dec 26, 2008 – Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Latisse (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes

Continued here:
Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse — First and Only Treatment Approved by the FDA for Hypotrichosis of…

FDA OKs 1st Eyelash Drug Latisse

December 28, 2008 · Posted in Healh News · Comment 

Title: FDA OKs 1st Eyelash Drug LatisseCategory: Health NewsCreated: 12/29/2008Last Editorial Review: 12/29/2008 (Source: MedicineNet Eyesight General) MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network , and receive $5 free advertising.

Originally posted here:
FDA OKs 1st Eyelash Drug Latisse

Allergan Eyelash Enhancer Approved

December 27, 2008 · Posted in Healh News · Comment 

Allergan received FDA approval to market Latisse, a beauty treatment that increases the length, thickness and darkness of eyelashes by using a drug the company developed to treat glaucoma. (Source: WSJ.com: Health)

Originally posted here:
Allergan Eyelash Enhancer Approved

FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes

December 8, 2008 · Posted in Healh News · Comment 

IRVINE, Calif.–(BUSINESS WIRE)–Dec 5, 2008 – Allergan, Inc. today announced the U.S.

More here:
FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes